Summary
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.
History
Actinium was founded in 1998 and is located in New York City. They have developed drug products for the treatment of advanced cancers, with the goal of providing more options for cancer patients and clinicians.
Mission
Actinium’s mission is to develop and commercialize novel, safe and effective therapies utilizing innovative approaches to target and selectively kill cancer cells and eliminate residual disease, while reducing systemic toxicity associated with current therapies.
Vision
Actinium is striving to become a leader in the evolution of cancer treatments, one patient at a time, through the discovery and development of safer, more effective targeted therapies for the treatment of advanced cancers.
Key Team
Dr. David Gould (Sr. VP of Corp. Devel. & Corp. Affairs)
Dr. Bernie Cunningham P.M.P., Ph.D. (Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management)
Dr. Qing Liang (VP & Head of Radiation Sciences)
Dr. Robert N. Daly M.S., Ph.D. (VP & Head of Clinical Operations)
Dr. Mamata Gokhale (VP & Global Head of Regulatory Affairs)
Dr. Avinash Desai M.D. (Chief Medical Officer)
Dr. Arun Swaminathan Ph.D. (Chief Bus. Officer)
Recognition and Awards
Actinium has been awarded numerous industry awards, including the Ernst & Young Entrepreneur of the Year Award, the American Association of Cancer Research Innovation Award, and the Science and Technology Award from the American Society of Hematology.
References
United States 